DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Novel Social Media Intervention For Older Br CA Patients

Not Applicable

Completed

Conditions: Breast Cancer Stage I
Breast Cancer Stage II
Breast Cancer Stage III

Interventions: Other: PatientsLikeMe (PLM)

First Posted Date: 2015-12-24

Last Posted Date: 2021-08-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 47

Registration Number: NCT02639208

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Phase 2

Active, not recruiting

Conditions: Inflammatory Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions: Drug: Eribulin
Drug: Adriamycin
Drug: Cyclophosphamide

First Posted Date: 2015-12-08

Last Posted Date: 2025-05-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT02623972

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Ibrutinib

First Posted Date: 2015-11-13

Last Posted Date: 2022-12-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT02604511

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massacusetts General Hospital, Boston, Massachusetts, United States

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

Phase 1

Terminated

Conditions: Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos
Rhabdoid Tumor
Rhabdomyosarcoma
Wilms Tumor
Clear Cell Renal Cell Carcinoma
Renal Tumor
Sarcoma
Soft Tissue Sarcoma
Sarcoma, Ewing
Ewing Sarcoma

Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2015-10-21

Last Posted Date: 2021-04-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT02581384

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Obinutuzumab
Drug: Ibrutinib

First Posted Date: 2015-09-01

Last Posted Date: 2025-02-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT02537613

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Lenalidomide for Adult Histiocyte Disorders

Phase 2

Active, not recruiting

Conditions: Langerhans Cell Histiocytosis (LCH)
Histiocytoses Erdheim-chester Disease
Histiocytic Sarcoma (HS)

Interventions: Drug: Lenalidomide

First Posted Date: 2015-08-14

Last Posted Date: 2025-05-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 12

Registration Number: NCT02523040

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The ICat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

Active, not recruiting

Conditions: Pediatric Solid Tumor

Interventions: Genetic: Genetic testing and GAIN report

First Posted Date: 2015-08-13

Last Posted Date: 2025-03-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 825

Registration Number: NCT02520713

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

and more 9 locations

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Phase 1

Completed

Conditions: Merkel Cell Carcinoma

Interventions: Drug: MLN0128

First Posted Date: 2015-08-04

Last Posted Date: 2020-12-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT02514824

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)

Completed

Conditions: Lung Cancer

Interventions: Other: VATS-associated best practices

First Posted Date: 2015-07-20

Last Posted Date: 2020-01-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 173

Registration Number: NCT02502695

Locations: 🇺🇸
Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
WellStar Medical Group, Austell, Georgia, United States

and more 3 locations

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Placebo
Drug: LY2452473

First Posted Date: 2015-07-16

Last Posted Date: 2021-09-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 114

Registration Number: NCT02499497

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
John Hopkins Medical Center, Baltimore, Maryland, United States
🇺🇸
Beth Israel Deaconess Medical Center (Referring site only), Boston, Massachusetts, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy